Can I read Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials on EtoBox?

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials by Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials about?

## Background Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile. ## Methods A literature-based meta-analysis to quantify the magnitude of benefit and safety of adding bevacizumab to chemotherapy for advanced breast cancer patients was conducted. Meta-regression and sensitivity analyses were also performed to identify additional predictors of outcome and to assess the influence of trial design. ## Results Five trials (3,841 patients) were gathered. A significant interaction according to treatment line was found for progression-free survival (PFS, p = 0.027); PFS was significantly improved for 1^st^ line (Hazard Ratio, HR 0.68, p < 0.0001), with a 1-yr absolute difference (AD) of 8.4% (number needed to treat, NNT 12). A non-significant trend was found in overall survival (OS), and in PFS for 2^nd^ line. Responses were improved with the addition of bevacizumab, without interaction between 1^st^ line (Relative Risk, RR 1.46, p < 0.0001) and 2^nd^ line (RR 1.58, p = 0.05). The most important toxicity was hypertensi

Who reads Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials?

Author

Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti

Publisher

BioMed Central; Springer (Biomed Central Ltd.); London: BioMed Central, 2008-; Springer Science and Business Media LLC; Society for Mining, Metallurgy and Exploration Inc. (ISSN 1756-9966)

Published

2011

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)